Subcutaneous Levodopa: A New Engine for the Vintage Molecule
| Title: | Subcutaneous Levodopa: A New Engine for the Vintage Molecule |
|---|---|
| Authors: | Karolina Poplawska-Domaszewicz, Lucia Batzu, Cristian Falup-Pecurariu, K. Ray Chaudhuri |
| Source: | Neurology and Therapy, Vol 13, Iss 4, Pp 1055-1068 (2024) |
| Publisher Information: | Adis, Springer Healthcare, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Neurology. Diseases of the nervous system |
| Subject Terms: | Parkinson’s disease, Foslevodopa, Subcutaneous, Continuous drug delivery, Early morning off, Neurology. Diseases of the nervous system, RC346-429 |
| More Details: | Abstract The management of Parkinson’s disease (PD) continues to evolve with advancements in non-oral levodopa-based therapies aiming to provide continuous drug delivery (CDD). Such therapies address the challenges posed by the emergence of motor fluctuations, dyskinesias, and non-motor fluctuations (NMF) associated with oral levodopa administration and contributing to define the advanced stage of PD. The key focus of this review is placed on subcutaneous foslevodopa/foscarbidopa (Foslevodopa/foscarbidopa) infusion, showcasing its recent clinical availability and efficacy in providing continuous levodopa delivery. While providing an overview of the other non-oral levodopa-based CDD systems, such as intrajejunal levodopa–carbidopa infusion and levodopa–entacapone–carbidopa infusion, we highlight the current promising evidence for Foslevodopa/foscarbidopa to improve, for example, “on time” without troublesome dyskinesia and reducing “off time” in people with advanced PD. Additionally, Foslevodopa/foscarbidopa demonstrates potential in managing early morning off periods, sleep quality and other motor and non-motor symptoms. Moreover, other non-oral CDD options such as ND0612 and DIZ102/DIZ101 are discussed, with focus on their pharmacokinetics/pharmacodynamics, efficacy, and safety profiles. While these advancements present new therapeutic avenues, long-term observational studies are warranted to elucidate their impact on existing PD therapies. Overall, this review provides insights into the evolving landscape of non-oral CDD therapies and offers a pragmatic approach for their integration into clinical practice. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2193-8253 2193-6536 |
| Relation: | https://doaj.org/toc/2193-8253; https://doaj.org/toc/2193-6536 |
| DOI: | 10.1007/s40120-024-00635-4 |
| Access URL: | https://doaj.org/article/edd550052ccd4efdb93128992956c14f |
| Accession Number: | edsdoj.550052ccd4efdb93128992956c14f |
| Database: | Directory of Open Access Journals |
| ISSN: | 21938253 21936536 |
|---|---|
| DOI: | 10.1007/s40120-024-00635-4 |
| Published in: | Neurology and Therapy |
| Language: | English |